Recent FDA Approval: Halozyme Therapeutics has sparked considerable attention on social media following the recent FDA approval of RYBREVANT FASPRO, co-formulated with their ENHANZE technology, for advanced EGFR-mutated non-small cell lung cancer. Many users are highlighting this as a significant milestone for the company’s growth in the biotech space. The buzz reflects optimism about potential revenue boosts from this development.
Legal Victory Impact: Discussions also center on a recent German court ruling granting Halozyme a preliminary injunction against a competitor’s product, seen as a major win for their patent portfolio. Some are speculating on social media about how this could strengthen their market position and lead to lucrative licensing deals. This news has fueled further interest in the stock’s future trajectory.
Note: This discussion summary was generated from an AI condensation of post data.
Halozyme Therapeutics Insider Trading Activity
Halozyme Therapeutics insiders have traded $HALO stock on the open market 58 times in the past 6 months. Of those trades, 0 have been purchases and 58 have been sales.
Here’s a breakdown of recent trading of $HALO stock by insiders over the last 6 months:
- HELEN TORLEY (PRESIDENT AND CEO) has made 0 purchases and 47 sales selling 376,569 shares for an estimated $24,456,411.
- NICOLE LABROSSE (SVP, CHIEF FINANCIAL OFFICER) has made 0 purchases and 4 sales selling 22,227 shares for an estimated $1,687,851.
- BERNADETTE CONNAUGHTON has made 0 purchases and 7 sales selling 8,829 shares for an estimated $641,533.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Halozyme Therapeutics Revenue
Halozyme Therapeutics had revenues of $354.3M in Q3 2025. This is an increase of 22.12% from the same period in the prior year.
You can track HALO financials on Quiver Quantitative's HALO stock page.
Halozyme Therapeutics Hedge Fund Activity
We have seen 298 institutional investors add shares of Halozyme Therapeutics stock to their portfolio, and 342 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- D. E. SHAW & CO., INC. added 1,631,571 shares (+160.1%) to their portfolio in Q3 2025, for an estimated $119,659,417
- UBS GROUP AG added 1,421,364 shares (+93.2%) to their portfolio in Q3 2025, for an estimated $104,242,835
- FEDERATED HERMES, INC. added 1,082,638 shares (+294.1%) to their portfolio in Q3 2025, for an estimated $79,400,670
- VOLORIDGE INVESTMENT MANAGEMENT, LLC added 1,057,902 shares (+inf%) to their portfolio in Q3 2025, for an estimated $77,586,532
- STATE STREET CORP removed 915,838 shares (-15.4%) from their portfolio in Q3 2025, for an estimated $67,167,558
- TWO SIGMA INVESTMENTS, LP added 876,086 shares (+199.2%) to their portfolio in Q3 2025, for an estimated $64,252,147
- ARTISAN PARTNERS LIMITED PARTNERSHIP removed 752,150 shares (-92.3%) from their portfolio in Q3 2025, for an estimated $55,162,681
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Halozyme Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $HALO in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 12/19/2025
- Benchmark issued a "Buy" rating on 09/24/2025
- JMP Securities issued a "Market Outperform" rating on 08/06/2025
To track analyst ratings and price targets for Halozyme Therapeutics, check out Quiver Quantitative's $HALO forecast page.
Halozyme Therapeutics Price Targets
Multiple analysts have issued price targets for $HALO recently. We have seen 9 analysts offer price targets for $HALO in the last 6 months, with a median target of $78.0.
Here are some recent targets:
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $90.0 on 12/19/2025
- Graig Suvannavejh from Goldman Sachs set a target price of $56.0 on 11/18/2025
- Jason Butler from Citizens set a target price of $92.0 on 11/04/2025
- Jessica Fye from JP Morgan set a target price of $65.0 on 10/27/2025
- Vikram Purohit from Morgan Stanley set a target price of $79.0 on 10/20/2025
- David Risinger from Leerink Partners set a target price of $70.0 on 10/14/2025
- Robert Wasserman from Benchmark set a target price of $90.0 on 09/24/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
